Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes

被引：3

作者：

Sanchez-Castro, Judit ^{[1
]}

Marco-Betes, Victor ^{[1
]}

Gomez-Arbones, Xavier ^{[1
,2
]}

Garcia-Cerecedo, Tomas ^{[1
]}

Lopez, Ricard ^{[1
]}

Talavera, Elisabeth ^{[1
]}

Fernandez-Ruiz, Sara ^{[3
]}

Adema, Vera ^{[3
]}

Marugan, Isabel ^{[4
]}

Luno, Elisa ^{[5
]}

Sanzo, Carmen ^{[5
]}

Vallespi, Teresa ^{[6
]}

Arenillas, Leonor ^{[7
]}

Marco-Buades, Josefa ^{[8
]}

Batlle, Ana ^{[9
]}

Buno, Ismael ^{[10
]}

Luisa Martin-Ramos, Maria ^{[11
]}

Blazquez-Rios, Beatriz ^{[12
]}

Collado-Nieto, Rosa ^{[13
]}

Teresa Vargas, Ma ^{[14
]}

Gonzalez-Martinez, Teresa ^{[15
]}

Sanz, Guillermo ^{[16
]}

Sole, Francesc ^{[3
]}

机构：

[1] Hosp Arnau Vilanova, Lleida, Spain

[2] Univ Lleida, Lleida, Spain

[3] Inst Recerca Leucemia Josep Carreras IJC, Barcelona 08916, Spain

[4] Univ Valencia, Hosp Clin, Valencia, Spain

[5] Hosp Univ Cent Asturias, Oviedo, Spain

[6] Hosp Valle De Hebron, Barcelona, Spain

[7] Hosp del Mar, Barcelona, Spain

[8] Hosp Gen Castellon, Castellon de La Plana, Spain

[9] Hosp Univ Marques Valdecilla, Santander, Spain

[10] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[11] Hosp Univ 12 Octubre, Madrid, Spain

[12] Hosp Basurto, Bilbao, Spain

[13] Hosp Gen Univ Valencia, Valencia, Spain

[14] Hosp Univ Virgen Macarena, Seville, Spain

[15] Hosp Clin Univ, Fdn Publ Galega Med Xenom, Santiago, Spain

[16] Hosp Univ & Politecn La Fe, Valencia, Spain

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 11期

关键词：

Myelodysplastic syndromes; cytogenetics; FISH; chromosome; 17; ACUTE MYELOID-LEUKEMIA; PROGNOSTIC SCORING SYSTEM; PREDICTING SURVIVAL; DELETION; MDS; KARYOTYPE;

D O I：

10.3109/10428194.2015.1028053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematological Cytogenetics. FISH detected - 17 or 17p abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed by CC: 0.9% of patients with a normal karyotype, 0% in non-informative cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 4.7% of cases with an abnormal karyotype not involving chr17. Our results suggest that applying FISH of 17p13 to identify the number of copies of the TP53 gene could be beneficial in patients with a complex karyotype. We recommend using FISH of 17p13 in young patients with a normal karyotype or non-informative cytogenetics, and always in isolated del(17p)

引用

页码：3183 / 3188

页数：6

共 50 条

[31] Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Montalban-Bravo, Guillermo
Kanagal-Shamanna, Rashmi
Benton, Christopher B.
Class, Caleb
Chien, Kelly S.
Sasaki, Koji
Naqvi, Kiran
Alvarado, Yesid
Kadia, Tapan M.
Ravandi, Farhad
Cortes, Jorge E.
Daver, Naval G.
Takahashi, Koichi
DiNardo, Courtney D.
Jabbour, Elias
Borthakur, Gautam M.
Pemmaraju, Naveen
Konopleva, Marina Y.
Pierce, Sherry A.
Bueso-Ramos, Carlos E.
Andreeff, Michael
Patel, Keyur P.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2019, 134
[32] TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
Yabe, Mariko
Omarbekova, Aidana Z.
Hsu, Meier
May, Hannah
Arcila, Maria E.
Liu, Ying
Dogan, Ahmet
Brunner, Andrew M.
Nardi, Valentina
Hasserjian, Robert P.
Klimek, Virginia M.
CANCERS, 2021, 13 (21)
[33] FLUORESCENCE IN-SITU HYBRIDIZATION IMPROVES THE DETECTION OF MONOSOMY-7 IN MYELODYSPLASTIC SYNDROMES
FLACTIF, M
LAI, JL
PREUDHOMME, C
FENAUX, P
LEUKEMIA, 1994, 8 (06) : 1012 - 1018
[34] Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations
Adema, Vera
Larrayoz, Maria J.
Calasanz, Maria J.
Palomo, Laura
Patino-Garcia, Ana
Agirre, Xabier
Hernandez-Rivas, Jesus M.
Lumbreras, Eva
Buno, Ismael
Martinez-Laperche, Carolina
Mallo, Mar
Garcia, Olga
Alvarez, Sara
Blazquez, Beatriz
Cervera, Jose
Luno, Elisa
Valiente, Alberto
Vallespi, Maria T.
Arenillas, Leonor
Collado, Rosa
Perez-Oteyza, Jaime
Sole, Francesc
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 137 - 141
[35] High resolution detection of chromosome abnormalities with single copy fluorescence in situ hybridization
Rogan, PK
Knoll, JHM
2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, 2004, : 73 - 76
[36] TP53 mutations in myelodysplastic syndrome
Misawa, S
Horiike, S
LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 417 - 422
[37] TP53 Abnormality in Myelodysplastic Syndrome
Huang, Fei
Chen, Yu
Zhu, Yuxing
Qiao, Chun
Qian, Sixuan
Li, Jianyong
Shen, Wenyi
BLOOD, 2019, 134
[38] Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bi, Xia
French, Zachary
Kasner, Margaret
Keiffer, Gina
Wilde, Lindsay
Palmisiano, Neil
BLOOD, 2020, 136
[39] TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
Sallman, David A.
McLemore, Amy F.
Aldrich, Amy L.
Komrokji, Rami S.
McGraw, Kathy L.
Dhawan, Abhishek
Geyer, Susan
Hou, Hsin-An
Eksioglu, Erika Adriana
Sullivan, Amy
Warren, Sarah
MacBeth, Kyle J.
Meggendorfer, Manja
Haferlach, Torsten
Boettcher, Steffen
Ebert, Benjamin L.
Al-Ali, Najla
Lancet, Jeffrey E.
Cleveland, John L.
Padron, Eric
List, Alan F.
BLOOD, 2020, 136 (24) : 2812 - 2823
[40] Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Takahashi, Koichi
Patel, Keyur
Bueso-Ramos, Carlos
Zhang, Jianhua
Gumbs, Curtis
Jabbour, Elias
Kadia, Tapan
Andreff, Michael
Konopleva, Marina
DiNardo, Courtney
Daver, Naval
Cortes, Jorge
Estrov, Zeev
Futreal, Andrew
Kantarjian, Hagop
Garcia-Manero, Guillermo
ONCOTARGET, 2016, 7 (12) : 14172 - 14187

← 1 2 3 4 5 →